Keele Research Repository

Article

Wheatley, D, Haviland, J, Patel, J, Sydenham, M, Alhasso, A, Chan, C, Cleator, S, Coles, C, Donovan, E, Kirby, A, Kirwan, C, Nabi, Z, Sawyer, E, Somaiah, N, Syndikus, I, Venables, K, Yarnold, J, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097 and Bliss, J (2022) First results of FAST-Forward phase 3 RCT nodal substudy: 3-year normal tissue effects. Radiotherapy and Oncology, 170. S75 - S76.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, JS, Kirby, AM, Somaiah, N, Wheatley, DA, Bliss, JM and Yarnold, JR (2021) Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation. Clinical Oncology.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, JS, Wheatley, DA, Sydenham, MA, Alhasso, A, Bloomfield, D, Chan, C, Churn, M, Cleator, S, Coles, CE, Emson, M, Goodman, A, Harnett, A, Hopwood, P, Kirby, AM, Kirwan, C, Morris, C, Nabi, Z, Sawyer, E, Somaiah, N, Stones, L, Syndikus, I, Wilcox, M, Bliss, JM and Yarnold, JR (2020) FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 5-year results. Radiotherapy and Oncology, 152 (S1). S346 - S347.

Brunt, AM, Haviland, JS, Wheatley, DA, Sydenham, MA, Alhasso, A, Bloomfield, DJ, Chan, C, Churn, M, Cleator, S, Coles, CE, Goodman, A, Harnett, A, Hopwood, P, Kirby, AM, Kirwan, CC, Morris, C, Nabi, Z, Sawyer, E, Somaiah, N, Stones, L, Syndikus, I, Bliss, JM, Yarnold, JR and FAST-Forward Trial Management Group, . (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet, 395 (10237). 1613 - 1626.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, J, Sydenham, M, Alhasso, A, Bloomfield, D, Chan, C, Churn, M, Cleator, S, Coles, C, Emson, M, Goodman, A, Griffin, C, Harnett, A, Hopwood, P, Kirby, A, Kirwan, C, Morris, C, Sawyer, E, Somaiah, N, Syndikus, I, Wilcox, M, Rada, Z, Wheatley, D, Bliss, J and Yarnold, J (2018) FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. British Journal of Cancer, 119 (11). 41 - 41.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, J, Sydenham, M, Al-hasso, A, Bloomfield, D, Chan, C, Churn, M, Cleator, S, Coles, C, Emson, M, Goodman, A, Griffin, C, Harnett, A, Hopwood, P, Kirby, A, Kirwan, C, Morris, C, Sawyer, E, Somaiah, N, Syndikus, I, Wilcox, M, Zotova, R, Wheatley, D, Bliss, J and Yarnold, J (2018) FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. Radiotherapy and Oncology, 127 (S1). S311 -S312.

Brunt, AM, Wheatley, D, Yarnold, J, Somaiah, N, Kelly, S, Harnett, A, Coles, C, Goodman, A, Bahl, A, Churn, M, Zotova, R, Sydenham, M, Griffin, CL, Morden, JP and Bliss, JM (2016) Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiotherapy and Oncology, 120 (1). pp. 114-118.